Pharma hasn’t traditionally been known as a sector that welcomed innovation from the outside. But now companies are putting “not invented here” bias aside as they seek to widen their aperture for innovation.
This month saw the launch of two open innovation initiatives by drugmakers. Novartis opened the first of a series of planned innovation labs, this one in San Francisco, as part of a larger project to collaborate with startups and tech companies to fuel innovation. Novo Nordisk kicked off an innovation challenge, asking startups to create digital tools to help manage diabetes.
Image: Novartis is opening a series of innovation labs, starting in San Francisco, as part of a project called Biome that’s designed to foster open innovation. Above, winners of a recent innovation challenge the drugmaker sponsored received membership in Biome. Photo courtesy Novartis.
